Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Pharmacogenet Genomics. 2011 Mar;21(3):130–135. doi: 10.1097/FPC.0b013e3283436b86

Fig. 1.

Fig. 1

Effect of VKORC1, CYP2C9, CYP4F2, APOE ε2, and CALU genetic polymorphisms on warfarin dose requirements in Egyptians. Bars represent mean warfarin dose required. Error bars represent standard deviation. (P<0.05 is considered significant, test done by analysis of variance). APOE ε2 was coded as 0, 1, and 2 copies.